| Followers | 7 |
| Posts | 5499 |
| Boards Moderated | 0 |
| Alias Born | 09/11/2013 |
Monday, October 06, 2014 2:12:24 PM
Thank you for your sage advice. I will certainly take it under advisement.
I do not, however, have a short strategy with NNVC.
Historically (I'd say from 2008 to 2013) I was a Long. I divested my long position and, fortunately, escaped with a slight advantage to the green side. I have abandoned my long position (and stance) and have taken interest in NNVC as a trading vehicle. As such, I have fared slightly better than when I maintained my long position for those many fruitless years.
I currently hold a small number of shares and sincerely hope the SP rises to a point where I can unload with a small profit.
I do not, however, have a short strategy with NNVC.
Historically (I'd say from 2008 to 2013) I was a Long. I divested my long position and, fortunately, escaped with a slight advantage to the green side. I have abandoned my long position (and stance) and have taken interest in NNVC as a trading vehicle. As such, I have fared slightly better than when I maintained my long position for those many fruitless years.
I currently hold a small number of shares and sincerely hope the SP rises to a point where I can unload with a small profit.
As should you as it should take that long for you to recover from your short strategy losses.
Recent NNVC News
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
